Bovine and human lactoferricin peptides: Chimeras and new cyclic analogs

BioMetals

Volumn 27, Issue 5, 2014, Pages 935-948

  Arias, Mauricio ^a   McDonald, Lindsey J ^a   Haney, Evan F ^a,b   Nazmi, Kamran ^c   Bolscher, Jan G M ^c   Vogel, Hans J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Click chemistry; Lactoferricin; Lactoferrin; Peptide cyclization; Sortase A

Indexed keywords

DISULFIDE; LACTOFERRICIN; SORTASE; ANTIMICROBIAL CATIONIC PEPTIDE; CYCLOPEPTIDE; HYBRID PROTEIN; LACTOFERRICIN B; LACTOFERRIN; LIPOSOME; PEPTIDE FRAGMENT;

ANTIMICROBIAL ACTIVITY; ARTICLE; CLICK CHEMISTRY; CYCLIZATION; DRUG MECHANISM; ESCHERICHIA COLI; HUMAN; INNER MEMBRANE; IONIC STRENGTH; MEMBRANE PERMEABILITY; NONHUMAN; AMINO ACID SEQUENCE; ANIMAL; BOVINE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; GENETICS; MOLECULAR GENETICS; PATHOGENICITY; PHYSIOLOGY; SPECIES DIFFERENCE;

BOVINAE; MAMMALIA;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CATTLE; CELL MEMBRANE PERMEABILITY; CLICK CHEMISTRY; ESCHERICHIA COLI; HUMANS; LACTOFERRIN; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; RECOMBINANT FUSION PROTEINS; SPECIES SPECIFICITY; UNILAMELLAR LIPOSOMES;

EID: 84910004130     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-014-9753-4     Document Type: Article

References (45)

1. Alexander DB, Iigo M, Yamauchi K, Suzui M (2012) Lactoferrin: an alternative view of its role in human biological fluids. Biochem Cell Biol 90:279-306. doi: 10.1139/O2012-013
2. Ames BN, Neufeld EF, Ginsberg V (1966) Assay of inorganic phosphate, total phosphate and phosphatases. Methods Enzymol 8:115-118. doi: 10.1016/0076-6879(66)08014-5
3. Arnold RR, Cole MF, McGhee JR (1977) A bactericidal effect for human lactoferrin. Science 197:263-265
4. Arnold RR, Russell JE, Champion WJ et al (1982) Bactericidal activity of human lactoferrin: differentiation from the stasis of iron deprivation. Infect Immun 35:792-799
5. Baker EN, Baker HM (2009) A structural framework for understanding the multifunctional character of lactoferrin. Biochimie 91:3-10. doi: 10.1016/j.biochi.2008.05.006
6. Bellamy W, Takase M, Wakabayashi H et al (1992a) Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J Appl Bacteriol 73:472-479
7. Bellamy W, Takase M, Yamauchi K et al (1992b) Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1121:130-136
8. Bolscher JGM, Adão R, Nazmi K et al (2009) Bactericidal activity of LFchimera is stronger and less sensitive to ionic strength than its constituent lactoferricin and lactoferrampin peptides. Biochimie 91:123-132. doi: 10.1016/j.biochi.2008.05.019
9. Bolscher JGM, Oudhoff MJ, Nazmi K et al (2011) Sortase A as a tool for high-yield histatin cyclization. FASEB J 25:2650-2658. doi: 10.1096/fj.11-182212
10. Brock JH (1980) Lactoferrin in human milk: its role in iron absorption and protection against enteric infection in the newborn infant. Arch Dis Child 55:417-421
11. Crommelin DJA (1984) Influence of lipid composition and ionic strength on the stability of liposomes. J Pharm Sci 73:1559-1563
12. Dathe M, Nikolenko H, Klose J, Bienert M (2004) Cyclization increases the antimicrobial activity and selectivity of arginine- and tryptophan-containing hexapeptides. Biochemistry 43:9140-9150. doi: 10.1021/bi035948v
13. Domingues MM, Castanho MARB, Santos NC (2008) What can light scattering spectroscopy do for membrane-active peptide studies? J Pept Sci 14:394-400. doi: 10.1002/psc
14. Drago-Serrano ME, de la Garza-Amaya M, Luna JS, Campos-Rodríguez R (2012) Lactoferrin-lipopolysaccharide (LPS) binding as key to antibacterial and antiendotoxic effects. Int Immunopharmacol 12:1-9. doi: 10.1016/j.intimp.2011.11.002
15. Epand RF, Pollard JE, Wright JO et al (2010) Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother 54:3708-3713. doi: 10.1128/AAC.00380-10
16. Gifford JL, Hunter HN, Vogel HJ (2005) Lactoferricin: a lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell Mol Life Sci 62:2588-2598. doi: 10.1007/s00018-005-5373-z
17. Haney EF, Nazmi K, Bolscher JGM, Vogel HJ (2012) Structural and biophysical characterization of an antimicrobial peptide chimera comprised of lactoferricin and lactoferrampin. Biochim Biophys Acta 1818:762-775. doi: 10.1016/j.bbamem.2011.11.023
18. Haukland HH, Ulvatne H, Sandvik K, Vorland LH (2001) The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett 508:389-393
19. Holland-Nell K, Meldal M (2011) Maintaining biological activity by using triazoles as disulfide bond mimetics. Angew Chemie 50:5204-5206. doi: 10.1002/anie.201005846
20. Hunter HN, Demcoe AR, Jenssen H et al (2005) Human lactoferricin is partially folded in aqueous solution and is better stabilized in a membrane mimetic solvent. Antimicrob Agents Chemother 49:3387-3395. doi: 10.1128/AAC.49.8.3387
21. Hwang PM, Zhou N, Shan X et al (1998) Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37:4288-4298. doi: 10.1021/bi972323m
22. Jenssen H, Hancock REW (2009) Antimicrobial properties of lactoferrin. Biochimie 91:19-29. doi: 10.1016/j.biochi.2008.05.015
23. Krijgsveld J, Zaat SAJ, Van Veelen PA et al (2000) Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 275:20374-20381
24. Latorre D, Berlutti F, Valenti P et al (2012) LF immunomodulatory strategies: mastering. Biochem Cell Biol 90:269-278. doi: 10.1139/O11-059
25. Legrand D, Elass E, Carpentier M, Mazurier J (2005) Lactoferrin: a modulator of immune and inflammatory responses. Cell Mol Life Sci 62:2549-2559. doi: 10.1007/s00018-005-5370-2
26. Li H, Aneja R, Chaiken I (2013) Click chemistry in peptide-based drug design. Molecules 18:9797-9817. doi: 10.3390/molecules18089797
27. Liu Y, Han F, Xie Y, Wang Y (2011) Comparative antimicrobial activity and mechanism of action of bovine lactoferricin-derived synthetic peptides. Biometals 24:1069-1078. doi: 10.1007/s10534-011-9465-y
28. Nguyen LT, Chau JK, Perry NA et al (2010) Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS ONE 5:11-18. doi: 10.1371/journal.pone.0012684
29. Nikaido H (1998) The role of outer membrane and efflux pumps in the resistance of gram-negative bacteria. Can we improve drug access? Drug Resist Updat 1:93-98. doi: 10.1016/S1368-7646(98)80023-X
30. Nikaido H (2003) Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 67:593-656. doi: 10.1128/MMBR.67.4.593
31. Oren Z, Shai Y (2000) Cyclization of a cytolytic amphipathic alpha-helical peptide and its diastereomer: effect on structure, interaction with model membranes, and biological function. Biochemistry 39:6103-6114. doi: 10.1021/bi992408i
32. Park CB, Yi KS, Matsuzaki K et al (2000) Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc Natl Acad Sci USA 97:8245-8250. doi: 10.1073/pnas.150518097
33. Punna S, Kaltgrad E, Finn MG (2005) "Clickable" agarose for affinity chromatography. Bioconjug Chem 16:1536-1541. doi: 10.1021/bc0501496
34. Sánchez L, Calvo M, Brock JH (1992) Biological role of lactoferrin. Arch Dis Child 67:657-661
35. Strøm MB, Haug BE, Rekdal Ø et al (2002) Important structural features of 15-residue lactoferricin derivatives and methods for improvement of antimicrobial activity. Biochem Cell Biol 80:65-74. doi: 10.1139/O01-236
36. Tomita M, Takase M, Bellamy W, Shimamura S (1994) A review: the active peptide of lactoferrin. Acta Paediatr Jpn 36:585-591
37. Ulvatne H, Haukland HH, Olsvik O, Vorland LH (2001) Lactoferricin B causes depolarization of the cytoplasmic membrane of Escherichia coli ATCC 25922 and fusion of negatively charged liposomes. FEBS Lett 492:62-65
38. Ulvatne H, Samuelsen Ø, Haukland HH et al (2004) Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 237:377-384. doi: 10.1016/j.femsle.2004.07.001
39. Umeyama M, Kira A, Nishimura K, Naito A (2006) Interactions of bovine lactoferricin with acidic phospholipid bilayers and its antimicrobial activity as studied by solid-state NMR. Biochim Biophys Acta 1758:1523-1528. doi: 10.1016/j.bbamem.2006.06.014
40. Valenti P, Antonini G (2005) Lactoferrin: an important host defence against microbial and viral attack. Cell Mol Life Sci 62:2576-2587. doi: 10.1007/s00018-005-5372-0
41. Visca P, Dalmastri C, Verzili D et al (1990) Interaction of lactoferrin with Escherichia coli cells and correlation with antibacterial activity. Med Microbiol Immunol 179:323-333
42. Vogel HJ (2012) Lactoferrin, a bird's eye view. Biochem Cell Biol 90:233-244. doi: 10.1139/O2012-016
43. Vorland LH, Ulvatne H, Andersen J et al (1998) Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand J Infect Dis 30:513-517
44. White CJ, Yudin AK (2011) Contemporary strategies for peptide macrocyclization. Nat Chem 3:509-524. doi: 10.1038/nchem.1062
45. Wiegand I, Hilpert K, Hancock REW (2008) Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substances. Nat Protoc 3:163-175. doi: 10.1038/nprot.2007.521